GlassScriptPhysician profile
Christopher B Skelley
NPI 1215905575
$9,076.11
in general payments reported to CMS, 2019-2025
45 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $1,214 · 2021: $1,586 · 2022: $1,356 · 2023: $1,146 · 2024: $1,110 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,465.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,338.10 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,141.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $950.83 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $449.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.29 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $443.51 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $435.83 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $353.03 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $328.49 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.12 | 2019-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $251.09 | 2019-2021 | |
| Abbott Laboratories | $236.77 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $212.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.05 | 2024-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $199.32 | 2019-2023 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Skelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.